Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | MPO | P05164 | 2/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 12/20 | 0.33 |
| ▸ | PDE4A | P27815 | 11/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 11/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.33 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24158778 | 0.90 | PDK1 (0.39) | MGLLPDK1PDK2LMNAPOLB | |
| SCHEMBL3548683 | 0.77 | NPC1 (0.39) | MGLLLMNAL3MBTL1 | |
| SCHEMBL21331023 | 0.75 | PDK1 (0.39) | MGLLPDK1PDK2POLB | |
| SCHEMBL21863668 | 0.74 | MPO (0.39) | MPO | |
| SCHEMBL23645428 | 0.73 | RAB9A (0.41) | MGLLLMNAPOLBL3MBTL1 | |
| SCHEMBL15273687 | 0.71 | HTR2A (0.39) | PDK1PDK2 | |
| SCHEMBL32681792 | 0.71 | TP53 (0.42) | LMNAPOLB | |
| SCHEMBL23652722 | 0.71 | MAP3K14 (0.32) | — | |
| SCHEMBL23652974 | 0.71 | GRM2 (0.36) | L3MBTL1 | |
| SCHEMBL30041996 | 0.71 | L3MBTL1 (0.32) | PDK1PDK2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116075516-A | Benzodiazepine derivatives useful for the treatment of respiratory syncytial virus infection | 辉瑞大药厂 | 2023-05-05 | — | — | CN | claimed |
| CN-112689636-B | Novel heteroatom aromatic amide derivative and pharmaceutical agent containing same | 科研制药株式会社 | 2024-08-20 | — | — | CN | disclosed |
| CN-116075516-A | Benzodiazepine derivatives useful for the treatment of respiratory syncytial virus infection | 辉瑞大药厂 | 2023-05-05 | — | — | CN | disclosed |
| EP-4093509-A1 | SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2022-11-30 | — | — | EP | disclosed |
| EP-3793565-B1 | MCL-1 INHIBITORS | GILEAD SCIENCES INC (US) | 2022-01-05 | — | — | EP | disclosed |
| CN-113332292-A | 6, 7-dihydro-5H-pyrazolo [5,1-b ] [1,3] oxazine-2-carboxamide compounds | 辉瑞公司 | 2021-09-03 | — | — | CN | disclosed |
| US-10738063-B2 | 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds | PFIZER INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-10323042-B2 | 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds | PFIZER INC. (US) | 2019-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738063-B2 | 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds | PDE4B, PDE5A, PDE3B | MGLL 3626/4885MPO 1363/4885PDE4B 1/4885 |
| US-10323042-B2 | 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds | CYP3A5, CYP3A7, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MGLL 4571/4885MPO 1569/4885PDE4B 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.